Show simple item record

dc.contributor.authorEgyházi, S
dc.contributor.authorMargison, Geoffrey P
dc.contributor.authorHansson, J
dc.contributor.authorRingborg, U
dc.date.accessioned2010-03-30T14:01:15Z
dc.date.available2010-03-30T14:01:15Z
dc.date.issued1997-01
dc.identifier.citationImmunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases. 1997, 33 (1):129-34 Eur. J. Canceren
dc.identifier.issn0959-8049
dc.identifier.pmid9071912
dc.identifier.doi10.1016/S0959-8049(96)00342-5
dc.identifier.urihttp://hdl.handle.net/10541/95257
dc.description.abstractIn tumour cell lines, an inverse relationship has been shown between susceptibility to the cytotoxic effects of the O6-alkylating agents and the expression of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). One of the most effective single agents in chemotherapy of metastatic melanoma is the O6-alkylating drug, dacarbazine. We therefore examined the distribution of MGMT in 37 skin and lymph node melanoma metastases using rabbit antihuman MGMT antiserum. MGMT expression was undetectable in tumours from 2 out of 34 patients and low in 4 further patients. When present, staining was mainly nuclear and showed a marked variation both among tumour cells within the same metastases, between separate metastases in the same patient and between tumours in different patients. MGMT expression determined by immunohistochemistry showed a relation to MGMT activity measurements, but was not related to the number of proliferating cells, as identified by staining with MIB-1 antibody. Tumour cells with moderate to strong immunostaining with MGMT antiserum were significantly more abundant in metastases excised after dacarbazine-based chemotherapy (n = 8) than in those excised before treatment (n = 29).
dc.language.isoenen
dc.subjectSkin Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Agents
dc.subject.meshCell Division
dc.subject.meshCell Nucleus
dc.subject.meshDacarbazine
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmunoenzyme Techniques
dc.subject.meshLymphatic Metastasis
dc.subject.meshMale
dc.subject.meshMelanoma
dc.subject.meshMethyltransferases
dc.subject.meshMiddle Aged
dc.subject.meshO(6)-Methylguanine-DNA Methyltransferase
dc.subject.meshSkin Neoplasms
dc.titleImmunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases.en
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, Karolinska Hospital, Stockholm, Sweden.en
dc.identifier.journalEuropean Journal of Canceren
html.description.abstractIn tumour cell lines, an inverse relationship has been shown between susceptibility to the cytotoxic effects of the O6-alkylating agents and the expression of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). One of the most effective single agents in chemotherapy of metastatic melanoma is the O6-alkylating drug, dacarbazine. We therefore examined the distribution of MGMT in 37 skin and lymph node melanoma metastases using rabbit antihuman MGMT antiserum. MGMT expression was undetectable in tumours from 2 out of 34 patients and low in 4 further patients. When present, staining was mainly nuclear and showed a marked variation both among tumour cells within the same metastases, between separate metastases in the same patient and between tumours in different patients. MGMT expression determined by immunohistochemistry showed a relation to MGMT activity measurements, but was not related to the number of proliferating cells, as identified by staining with MIB-1 antibody. Tumour cells with moderate to strong immunostaining with MGMT antiserum were significantly more abundant in metastases excised after dacarbazine-based chemotherapy (n = 8) than in those excised before treatment (n = 29).


Files in this item

This item appears in the following Collection(s)

Show simple item record